Composite and elementary natures of a1(1260) meson

We develop a practical method to analyze the mixing structure of hadrons consisting of two components of quark-composite and hadronic composite. As an example we investigate the properties of the axial vector meson a1(1260) and discuss its mixing properties quantitatively. We also make reference to the large Nc procedure and its limitation for the classification of such a mixed state.Comment: 13 pages, 4 figure

Hadron resonances with coexistence of different natures

We discuss coexistence/mixing of different natures of hadronic composite (molecule) and elementary (quark-intrinsic) ones in hadron resonances. The discussions here are based on our previous publications on the origin of hadron resonances \cite{Hyodo:2008xr}, exotic $\bar D$ meson-nucleons as hadronic composites containing one anti-heavy quark \cite{Yamaguchi:2011xb}, and the study of $a_1$ as a typical example to show explicitly the mixing of the two different natures \cite{Nagahiro:2011jn}. In all cases, interactions are derived from the chiral dynamics of the light flavor sector. These interactions generate in various cases hadronic composite/molecule states, serving varieties of structure beyond the conventional quark model.Comment: Proceedings for Hadron Nuclear Physics (HNP) 2011, Pohang, Korea, February 21-24 (2011

Proton beam therapy with concurrent chemotherapy is feasible in children with newly diagnosed rhabdomyosarcoma

BACKGROUND: The optimal treatment for rhabdomyosarcoma (RMS) requires multidisciplinary treatment with chemotherapy, surgery, and radiotherapy. Surgery and radiotherapy are integral to the local control (LC) of RMS. However, postsurgical and radiotherapy-related complications could develop according to the local therapy and tumor location. In this study, we conducted a single-center analysis of the outcomes and toxicity of multidisciplinary treatment using proton beam therapy (PBT) for pediatric RMS. MATERIALS AND METHODS: RMS patients aged younger than 20 years whose RMS was newly diagnosed and who underwent PBT at University of Tsukuba Hospital (UTH) during the period from 2009 to 2019 were enrolled in this study. The patients’ clinical information was collected by retrospective medical record review. RESULTS: Forty-eight patients were included. The 3-year progression-free survival (PFS) and overall survival (OS) rates of all the patients were 68.8% and 94.2%, respectively. The 3-year PFS rates achieved with radical resection, conservative resection, and biopsy only were 65.3%, 83.3%, and 67.6%, respectively (p = 0.721). The 3-year LC rates achieved with radical resection, conservative resection, and biopsy only were 90.9%, 83.3%, and 72.9%, respectively (p = 0.548). Grade 3 or higher mucositis/dermatitis occurred in 14 patients. Although the days of opioid use due to mucositis/dermatitis during the chemotherapy with PBT were longer than those during the chemotherapy without PBT [6.1 and 1.6 (mean), respectively, p = 0.001], the frequencies of fever and elevation of C-reactive protein were equivalent. CONCLUSIONS: Multidisciplinary therapy containing PBT was feasible and provided a relatively fair 3-year PFS, even in children with newly diagnosed RMS without severe toxicity